Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Merck
Boehringer Ingelheim
Express Scripts
Dow

Last Updated: December 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,993,568

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,993,568
Title:Compounds comprising self-immolative group
Abstract: Provided are methods of use of compounds comprising a self-immolative group, which compounds may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
Inventor(s): Kim; Yong Zu (Daejeon, KR), Park; Tae Kyo (Daejeon, KR), Woo; Sung Ho (Daejeon, KR), Kim; Sun Young (Daejeon, KR), Cho; Jong Un (Daejeon, KR), Jung; Doo Hwan (Daejeon, KR), Min; Ji Young (Daejeon, KR), Lee; Hyang Sook (Daejeon, KR), Park; Yun Hee (Daejeon, KR), Ryu; Jeong Hee (Daejeon, KR), Oh; Kyu Man (Daejeon, KR), Oh; Yeong Soo (Daejeon, KR), Chae; Jeiwook (Daejeon, KR), Song; Ho Young (Daejeon, KR), Chung; Chul-Woong (Daejeon, KR), Yang; Jeon (Daejeon, KR)
Assignee: LegoChem Biosciences, Inc. (Daejeon, KR)
Application Number:14/898,932
Patent Claims:1. A method of treating a disease selected from an autoimmune disorder, a cancer, a viral infection, a bacterial infection, a fungal infection, and a parasitic infection, comprising administering an antibody-drug conjugate comprising a self-immolative group represented by the following Chemical Formula 1: ##STR00030## G is a glucuronic acid moiety or ##STR00031## wherein R.sub.3 is hydrogen or a carboxyl protecting group, and each R.sub.4 is independently hydrogen or a hydroxyl protecting group; A is an antibody; B is an active agent; W is --C(O)--, --C(O)NR'--, --C(O)O--, --SO.sub.2NR'--, --P(O)R''NR'--, --SONR'--, or --PO.sub.2NR'--, in each case wherein the C(O), S, or P is directly bound to the phenyl ring, and R' and R'' are each independently hydrogen, (C.sub.1-C.sub.8)alkyl, (C.sub.3-C.sub.8)cycloalkyl, (C.sub.1-C.sub.8)alkoxy, (C.sub.1-C.sub.8)alkylthio, mono- or di-(C.sub.1-C.sub.8)alkylamino, (C.sub.3-C.sub.20)heteroaryl or (C.sub.6-C.sub.20)aryl; Z is hydrogen, (C.sub.1-C.sub.8)alkyl, halogen, cyano, or nitro; n is an integer of 1 to 3, and when n is an integer of 2 or more, each of the Z(s) are the same as or different from each other; L is a linker connecting A and W, comprising at least one isoprenyl derivative unit represented by the following Chemical Formula A, which is recognized by an isoprenoid transferase ##STR00032## and R.sub.1 and R.sub.2 are each independently hydrogen, (C.sub.1-C.sub.8)alkyl, or (C.sub.3-C.sub.8)cycloalkyl.

2. The method of claim 1, wherein G is ##STR00033## R.sub.3 is hydrogen or a carboxyl protecting group, and R.sub.4(s) are each independently hydrogen or a hydroxyl protecting group.

3. The method of claim 1, wherein W is --C(O)--, --C(O)NR'--, or --C(O)O--.

4. The method of claim 1, wherein the linker L is an alkylene having 1 to 50 carbon atoms and satisfies at least one of the following (i) to (iv): (i) the alkylene includes at least one unsaturated bond, (ii) the alkylene includes at least one heteroarylene, (iii) at least one carbon atom of the alkylene is replaced with one or more hetero atoms selected from nitrogen (N), oxygen (O), and sulfur (S), and (iv) the alkylene is substituted with one or more alkyls having 1 to 20 carbon atoms.

5. The method of claim 1, wherein the linker L further includes a linking moiety represented by Chemical Formula B, C, D, or E: ##STR00034## L.sub.1 is a single bond or alkylene having 1 to 30 carbon atoms; R.sub.11 is hydrogen or alkyl having 1 to 10 carbon atoms; and L.sub.2 is alkylene having 1 to 30 carbon atoms.

6. The method of claim 5, wherein the linker L further includes a connection unit represented by the following Chemical Formula F or G: --(CH.sub.2).sub.r(V(CH.sub.2).sub.p).sub.q-- [Chemical Formula F] --(CH.sub.2CH.sub.2X).sub.w-- [Chemical Formula G] V is a single bond, --O--, --S--, --NR.sub.21--, --C(O)NR.sub.22--, --NR.sub.23C(O)--, --NR.sub.24SO.sub.2--, or --SO.sub.2NR.sub.25--; X is --O--, (C.sub.1-C.sub.8)alkylene, or --NR.sub.21--; R.sub.21 to R.sub.25 are each independently hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkyl(C.sub.6-C.sub.20)aryl, or (C.sub.1-C.sub.6)alkyl(C.sub.3-C.sub.20)heteroaryl; r is an integer of 1 to 10; p is an integer of 0 to 10; q is an integer of 1 to 10; and w is an integer of 1 to 10.

7. The method of claim 1, wherein the antibody comprises an amino acid motif recognizable by an isoprenoid transferase.

8. The method of claim 7, wherein the antibody further comprises a spacer unit comprising an amino acid, an oligopeptide, or a polypeptide between the antibody and the amino acid motif.

9. The method of claim 7, wherein the antibody is covalently bonded to the linker L through the amino acid motif.

10. The method of claim 9, wherein the antibody comprises a C-terminus that is a C-terminus of a light chain or a heavy chain of the antibody.

11. The method of claim 7, wherein the isoprenoid transferase is farnesyl protein transferase (FTase) or geranylgeranyl transferase (GGTase).

12. The method of claim 1, wherein the antibody is selected from intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments, single chain Fv (scFv) mutants, multispecific antibodies, bispecific antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins including an antigen determination portion of an antibody, and other modified immunoglobulin molecules including an antigen recognition site.

13. The method of claim 12, wherein the antibody is selected from muromonab-CD3, abciximab, rituximab, daclizumab, palivizumab, infliximab, trastuzumab, etanercept, basiliximab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, adalimumab, alefacept, omalizumab, efalizumab, tositumomab-I.sup.131, cetuximab, bevacizumab, natalizumab, ranibizumab, panitumumab, eculizumab, rilonacept, certolizumab pegol, romiplostim, belimumab, tocilizumab, atlizumab, mepolizumab, pertuzumab, tremelimumab, ticilimumab, inotuzumab ozogamicin, aflibercept, catumaxomab, pregovomab, motavizumab, efumgumab, raxibacumab, and veltuzumab.

14. The method of claim 12, wherein the antibody is a monoclonal antibody.

15. The method of claim 7, wherein the amino acid motif is CYYX, XXCC, XCXC, or CXX, C representing cysteine, Y representing an aliphatic amino acid, and X representing an amino acid that determines a substrate specificity of the isoprenoid transferase.

16. The method of claim 1, wherein the active agent is a drug, a toxin, an affinity ligand, a detection probe, or a combination thereof.

17. The method of claim 1, wherein the active agent is an immunomodulatory compound, an anticancer agent, an antiviral agent, an antibacterial agent, an antifungal agent, an antiparasitic agent, or a combination thereof.

18. The method of claim 7, wherein the amino acid motif is (G).sub.zCVIM (SEQ ID NO: 1) or (G).sub.zCVLL (SEQ ID NO: 2), with G representing a glycine unit, and z being an integer of 0 to 20.

19. The method of claim 18, wherein the antibody-drug conjugate has a structure selected from: ##STR00035## wherein: Z is hydrogen, (C.sub.1-C.sub.8)alkyl, halogen, cyano, or nitro; X is --O--, (C.sub.1-C.sub.8)alkylene, or --NR.sub.21--; R.sub.21 is hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkyl(C.sub.6-C.sub.20)aryl, or (C.sub.1-C.sub.6)alkyl(C.sub.3-C.sub.20)heteroaryl; n is an integer of 1 to 3, and when n is an integer of 2 or more, each of the Z(s) are the same as or different from each other; r is an integer of 1 to 10; q is an integer of 1 to 10; w is an integer of 1 to 10; x is an integer of 0 to 10; g is an integer of 1 to 10; B is a drug having a structure selected from the following structures ##STR00036## ##STR00037## and y is an integer of 1 to 10.

20. The method of claim 1, wherein the disease is an autoimmune disorder.

21. The method of claim 1, wherein the disease is a cancer.

22. The method of claim 1, wherein the disease is a viral infection.

23. The method of claim 1, wherein the disease is a bacterial infection.

24. The method of claim 1, wherein the disease is a fungal infection.

25. The method of claim 1, wherein the disease is a parasitic infection.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
South Korea10-2014-0064360May 28, 2014
South Korea10-2015-0073161May 26, 2015
PCT Information
PCT FiledMay 27, 2015PCT Application Number:PCT/KR2015/005299
PCT Publication Date:December 03, 2015PCT Publication Number:WO2015/182984

Details for Patent 9,993,568

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 002 1998-05-12   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Baxter
Johnson and Johnson
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.